株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

非アルコール性脂肪性肝炎 (NASA):市場予測 2026年

Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026

発行 GlobalData 商品コード 737761
出版日 ページ情報 英文 56 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.17円で換算しております。
Back to Top
非アルコール性脂肪性肝炎 (NASA):市場予測 2026年 Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026
出版日: 2018年09月28日 ページ情報: 英文 56 Pages
概要

当レポートでは、世界における非アルコール性脂肪性肝炎 (NASA)の治療薬市場について調査し、市場に影響を及ぼす主要なイベントについて分析するほか、市場拡大の主な促進要因、主なアンメットニーズと開発中の治療薬のニーズへの対応見通しなどについてまとめています。

第1章 ダイナミック市場予測の概要

第2章 エグゼクティブサマリー

第3章 イベント1:肝硬変を有するNASH患者のための潜在的な治療アルゴリズムの理解が広がる

  • 主なイベントのアップデート
  • NASH F4患者を標的とした治療薬の競合情勢
  • 患者セグメント間を差別化するための新たな薬価モデル
  • F4患者セグメントにおけるNASHパイプラインの競合の拡大
  • 医師の考え
  • サマリー
  • ソース

第4章 イベント2:特定のフェーズII NASH治療薬の有効性データの初めての公表

  • 主なイベントのアップデート
  • 予測に追加される新薬の競合情勢
  • 肝脂肪含量の低下を示す4つのフェーズII治療薬
  • サマリー
  • ソース

第5章 イベント3:NASHの併用療法

  • 主なイベントのアップデート
  • Gileadは併用療法に向けてNASH戦略を変更
  • 医師の考え
  • サマリー
  • ソース

第6章 イベント4:新しいフェーズII有効性データの公表はNASHパイプラインの競合情勢を変化

  • 主なイベントのアップデート
  • よりポジティブなフェーズIIのデータでサポートされるCenicriviroc (セニクリビロック) およびIMM-124E
  • GalmedのAramchol はフェーズIIBにおける有効性が低い
  • 最近公表された有効性データを持つ治療薬の競合情勢
  • サマリー
  • ソース

第7章 イベントカレンダー

第8章 付録

目次
Product Code: GDHC005FS

Therapeutic options for Non-Alcoholic Steatohepatitis (NASH are currently very limited, with Vitamin E being the standard of care for patients. This leaves significant unmet need for the disease and, coupled with high disease prevalence in developed countries, results in enticing opportunities for drug developers.

As such, there is a very active pipeline for Non-Alcoholic Steatohepatitis (NASH, and many new products are expected to launch over the next 10 years. However, there is still uncertainty over how the Non-Alcoholic Steatohepatitis (NASH treatment landscape will develop as these new products launch.

Non-Alcoholic Steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of a fatty, inflamed, and damaged liver. It resembles alcoholic liver disease but occurs in people who drink little or no alcohol, and is a highly progressed form of non-alcoholic fatty liver disease (NAFLD). Non-Alcoholic Steatohepatitis (NASH is becoming increasingly common with the alarming epidemic of obesity and carries the risk for more aggressive liver diseases such as cirrhosis, liver failure, and in some rare instances, hepatocellular cancer.

"Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026", consists of a slide deck detailing key market-impacting events which reflects the projected influence of these events on the future NASH market.

The Key Events covered in this Non-Alcoholic Steatohepatitis (NASH) Dynamic Market Forecast include -

  • Increased Understanding of Potential Treatment Algorithms for NASH Patients With Cirrhosis.
  • First Publication of Efficacy Data for Several Phase II NASH Drugs.
  • Development of Combination Therapies for NASH.
  • Publication of New Phase II Efficacy Data Shifts Competitive Landscape for NASH Pipeline.

Furthermore, the report answers the following Key Question arising in the Non-Alcoholic Steatohepatitis (NASH) market -

  • The Non-Alcoholic Steatohepatitis (NASH) market is poised to undergo rapid expansion during the forecast period and beyond. What are the main drivers of this expansion?
  • What are the main unmet needs in Non-Alcoholic Steatohepatitis (NASH)? Will the drugs under development fulfill these needs?
  • Which patients are the most likely to receive drug treatment for Non-Alcoholic Steatohepatitis (NASH) during the forecast period, and which patients are unlikely to be reimbursed?

Scope:

Components of the slide deck include -

  • Timeline of market-impacting events
  • Key clinical trial landscape updates
  • Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
  • Overview of updates to the forecast model based on anticipated future impact of events
  • Forward-looking events calendar listing expected key updates to the NASH competitive space through September 2019

Other events included in the analysis include -

  • Regulatory filings
  • Approval decisions
  • Pricing changes
  • Patent litigation
  • Clinical trial data announcements
  • Clinical trial failures
  • Clinical trial timeline updates.

Reasons to buy:

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global NASH therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NASH therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Dynamic Market Forecast Overview

  • 1.1. Related Reports
  • 1.2. Upcoming Related Reports

2. Executive Summary

  • 2.1. Key Updates to NASH Market Dynamics
  • 2.2. Key Events in Update
  • 2.3. Clinical Trial Landscape Updates
  • 2.4. Competitive Assessment of Late-Stage Pipeline
  • 2.5. Market Insight on Key Events

3. Event 1: Increased Understanding of Potential Treatment Algorithms for NASH Patients With Cirrhosis

  • 3.1. Key Event Updates
  • 3.2. Competitive Landscape of Drugs Targeting NASH F4 Patients
  • 3.3. New Pricing Model to Differentiate Between Patient Segments
  • 3.4. Increased competition in the NASH Pipeline Within the F4 Patient Segment
  • 3.5. What Do Physicians Think?
  • 3.6. Summary
  • 3.7. Sources

4. Event 2: First Publication of Efficacy Data for Certain Phase II NASH Drugs

  • 4.1. Key Event Updates
  • 4.2. Competitive Landscape of New Drugs added to Forecast
  • 4.3. Four Phase II Drugs Shown to Lower Liver Fat Content
  • 4.4. Summary
  • 4.5. Sources

5. Event 3: Combination Therapies for NASH

  • 5.1. Key Event Updates
  • 5.2. Gilead Shifts NASH Strategy Towards Combination Therapies
  • 5.3. What Do Physicians Think
  • 5.4. Summary
  • 5.5. Sources

6. Event 4: Publication of New Phase II Efficacy Data Shifts Competitive Landscape for NASH Pipeline

  • 6.1. Key Event Updates
  • 6.2. Cenicriviroc and IMM-124E Supported by More Positive Phase II Data
  • 6.3. Poor Phase Iib Efficacy results for Galmed's Aramchol
  • 6.4. Competitive Landscape of Drugs With Recently Published Efficacy Data
  • 6.5. Summary
  • 6.6. Sources

7. Events Calendar

  • 7.1. Key Events Expected to Occur in October 2018 - September 2019

8. Appendix

  • 8.1. Methodology
  • 8.2. Primary Research
  • 8.3. About the Authors
  • 8.4. About GlobalData
  • 8.5. Contact Us
  • 8.6. Disclaimer
Back to Top